Testing 9MW3011 for patients with non-transfusion-dependent beta-thalassemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase Ib study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 9MW3011 in patients diagnosed with non-transfusion-dependent beta-thalassemia. A total of 40 subjects will be enrolled and assigned to four dosage cohorts, with participants randomized in a 4:1 ratio to receive either 9MW3011 or a placebo via intravenous infusion. The study aims to gather comprehensive data on the effects of the drug over multiple ascending doses.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Male and female subjects aged 18 to 65 years (inclusive)
2. Subject must have a documented genetic diagnosis of β-thalassemia or hemoglobin E/ β-thalassemia
3. Subjects must meet the criteria for non-transfusion-dependent thalassemia
4. Subjects must have a baseline hemoglobin level between 70-100 g/L(inclusive), based on 2 consecutive measurements taken at least 1 week apart within 4 weeks before randomization
5. Subjects must have evidence of iron overload during screening
6. Subject must have performance status: Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
7. Subjects must fully understand the study procedures and methods, voluntarily participate in the trial, and sign an informed consent form

Key Exclusion Criteria:

1. Subjects diagnosed with alpha-thalassemia
2. Subjects diagnosed with HbS/beta-thalassemia or transfusion-dependent beta-thalassemia
3. Subjects exhibit severe iron overload at the time of screening
4. In addition to thalassemia, subjects have any other forms of anemia and hematological disorders that the investigator assesses may compromise safety or influence study outcomes
5. Combined with any significant systemic diseases or psychiatric disorders
6. Subjects have New York Heart Association (NYHA) Class III-IV heart failure and other cardiovascular diseases within 6 months prior to screening or currently present
7. During the screening or baseline period, subjects exhibiting a QTcF interval of ≥450ms for males and ≥470ms for females on a 12-lead electrocardiogram (ECG), or presenting an abnormal 12-lead ECG with clinical significance
8. Uncontrolled hypertension before screening
9. A history of malignant neoplasm occurring within the last five years
10. Severe infection requiring hospitalization or intravenous antimicrobial therapy, or uncontrolled systemic bacterial, fungal, or viral active infection
11. Subject have received concomitant treatment that was not permitted by the protocol
12. Subjects whose hematological parameters did not meet the inclusion criteria during screening
13. Subjects with a history of substance abuse, as well as those who yield positive results on substance abuse screening
14. Subjects who are unable to undergo MRI scans
15. Pregnant or lactating women
16. Subjects presenting any other factors deemed unsuitable for participation assessed by the investigator

Where it's running

• The first Affiliated Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting
• Hainan General Hospital
  Haikou, Hainan, China Recruiting

Study contacts

• Study coordinator: Yongrong Lai
• Email: laiyongrong@hotmail.com
• Phone: +8607715356304

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Thalidomide with Danazol and Prednisolone for difficult beta-thalassemia in children

  This trial tests whether adding danazol and prednisolone to thalidomide helps children with transfusion-dependent beta-thalassemia who did not respond to thalidomide alone.

  Recruiting Phase 3 Khyber Medical University Peshawar · Peshawar, Khyber Pakhtunkhwa · NCT07884773

• Partial stem cell transplant for sickle cell disease and beta-thalassemia using matched donors

  This study tests a partial stem cell transplant from matched donors to help people with severe sickle cell disease or beta-thalassemia see if more donor cells can persist long-term.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07599176

• Gene editing of your own blood stem cells to boost fetal hemoglobin for severe sickle cell disease and beta-thalassemia

  This trial will test whether editing a specific gene in patients' own blood stem cells can raise fetal hemoglobin and reduce symptoms in people aged 13–40 with severe sickle cell disease or transfusion-dependent beta-thalassemia.

  Recruiting Phase 1 Boston Children's Hospital · Boston, Massachusetts · NCT06647979

• Long-term follow-up for patients treated with CS-101

  This study is checking how safe and effective the CS-101 treatment is for people who had it before, by following them for up to two years to see how they’re doing.

  Recruiting Children's Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06479616

• Observational study on patients with Beta-Thalassemia treated with betibeglogene autotemcel

  This study is looking at how well betibeglogene autotemcel works and its long-term safety for people with beta-thalassemia who have already received this treatment.

  Recruiting at 6 sites Genetix Biotherapeutics Inc. · Oakland, California and 5 other locations · NCT06271512

• Assessing the safety of luspatercept in Korean patients with myelodysplastic syndrome or beta thalassemia

  This study is testing how safe the drug luspatercept is for adult Korean patients with myelodysplastic syndrome or beta thalassemia while they are being treated.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06073860

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.